Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00047580 · ClinicalTrials.gov registry record · Phase 3

Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.

A Phase 3 study of Stroke and Multiple Sclerosis, sponsored by Elan Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target
16
Study locations

NCT00047580: Completed Phase 3 study of Stroke and Multiple Sclerosis, sponsored by Elan Pharmaceuticals.

NCT00047580 is a Phase 3 study of Stroke and Multiple Sclerosis that has completed, run by Elan Pharmaceuticals. The registered enrollment target is 120 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00047580, a Phase 3 study of Stroke and Multiple Sclerosis, has completed, sponsored by Elan Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target
16
Study locations

Study Summary

This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted state (before a meal) in patients with moderate to severe spasticity.

Interventions

  • DRUG tizanidine hydrochloride capsule

Study Locations (16)

California

  • The Neurology Center - Encinitas
  • Northridge Neurological Center - Northridge
  • The Neurology Center - Oceanside
  • Neurology Medical Group of Diablo Valley - Walnut Creek

Florida

  • Neurology Clinic Research Institution - Plantation
  • Axiom Clinical Research - Tampa

Georgia

  • Comprehensive Neurology Specialists, PC - Atlanta
  • Neurotrials Research, Inc. - Atlanta

Arizona

  • Radiant Research - Tucson

Colorado

  • Colorado Neurology Movement Disorders Center - Englewood

Connecticut

  • Yale Center for MS Treatment and Research - New Haven

Illinois

  • Springfield Clinic Neuroscience Institute - Springfield

Minnesota

  • The Minneapolis Clinic of Neurology, Ltd. - Minneapolis

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2002-06
Est. Completion 2002-09
Phase Phase 3
Elan Pharmaceuticals

5 total trials

What the finished NCT00047580 record still lists

NCT00047580 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which tizanidine hydrochloride capsule is the first listed.

NCT00047580 lists 16 locations in 11 states (California, Florida, Georgia).

Frequently Asked Questions

What is clinical trial NCT00047580 about?

NCT00047580 is a clinical study titled "Comparison of Safety and Efficacy of Tizanidine Hydrochloride Capsules Versus Zanaflex® (Tizanidine Hydrochloride Tablets) Taken While in the Fed State (Just After a Meal) and in the Fasted State (Before a Meal) in Patients With Moderate to Severe Spasticity.". This study is being conducted to compare the impact of somnolence (sleepiness) on cognition (awareness) as well as the safety and effectiveness of tizanidine hydrochloride capsules versus Zanaflex® (tizanidine hydrochloride tablets) taken while in the fed state (just after a meal) and in the fasted ...

What is the current status of trial NCT00047580?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2002-06. Estimated completion is 2002-09.

What conditions does trial NCT00047580 study?

This clinical trial studies the following conditions: Stroke, Multiple Sclerosis, Spinal Cord Injury, Muscle Spasticity.

What interventions are being tested in trial NCT00047580?

The interventions under investigation include: tizanidine hydrochloride capsule (DRUG).

Who is sponsoring clinical trial NCT00047580?

This trial is sponsored by Elan Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00047580 being conducted?

This trial has 16 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00047580's enrollment target sits among peer trials

120 117th of 454 higher than 329 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00047580, the US trial registry maintained by the National Library of Medicine. NCT00047580 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.